Adaptive Biotechnologies: president and COO Julie Rubinstein sold 35,643 shares

What happened

• The filing says Julie Rubinstein, president and chief operating officer, exercised options for 11,881 shares on each of Oct 22, Oct 23 and Oct 26, 2026 (total 35,643 shares) at $12.14 per share for $144,235 per exercise and $432,705 in total.
• The filing says Rubinstein sold a total of 35,643 shares in open market transactions on Oct 22, Oct 23 and Oct 26, 2026 for aggregate proceeds of $897,457 (individual sales and proceeds listed below).

Key details

• Transaction dates and prices reported:
  • Oct 22, 2026: exercised 11,881 shares at $12.14 (acquired for $144,235); sold 10,181 shares at a weighted-average $24.38 for $248,213 (prices ranged $23.96 to $24.89 per footnote F2); sold 1,700 shares at $25.29 for $42,993.
  • Oct 23, 2026: exercised 11,881 shares at $12.14 (acquired for $144,235); sold 4,500 shares at $24.50 for $110,250 (weighted-average per F4); sold 7,381 shares at $25.28 for $186,592 (prices ranged $24.96 to $25.59 per F3).
  • Oct 26, 2026: exercised 11,881 shares at $12.14 (acquired for $144,235); sold 8,503 shares at $25.94 for $220,568 (prices ranged $25.25 to $26.25 per F6); sold 3,378 shares at $26.30 for $88,841 (prices ranged $26.25 to $26.42 per F7).
• Shares owned after the transactions: not reported in this Form 4 excerpt.
• Footnotes of note:
  • F1: transactions were effected pursuant to a Rule 10b5-1 trading plan adopted Nov 18, 2025.
  • F2–F7: reported sale prices are weighted averages with ranges provided in the footnotes.
  • F8: the option was fully vested and exercisable.
• Form 4 filed on Oct 26, 2026 (accession 0001780664-26-000045).

Why it may matter

• The filing shows Rubinstein exercised options and sold the same number of shares acquired (the exercises and sales match at 35,643 shares), indicating the transactions involved exercising options followed by market sales (cashless exercise/sale).
• The filing does not show why the insider traded or why the company acted.